Proof of Principle

English

 

Better known for their destructive feeding habits, cabbage looper moth (Trichoplusia ni) caterpillars are proving to be a useful new tool in the production of human protein.
Carboxylesterase 1
 
The ability to produce large quantities of specific human proteins is crucial for life sciences research, and it is at the heart of the biotechnology and biomedical industries. The most traditional and widely used protein expression methods are based on cell cultures: Human DNA is introduced into bacteria, yeast or animal cell lines, where it “hijacks” the cells’ protein-making machinery and tricks it into producing human protein instead.

Though effective, these methods can be very expensive and time-consuming. A new protein expression system using whole insect larvae offers a potential alternative, cost-effective method of producing large quantities of human proteins. Before such methods can be employed, however, one question must be answered: Are the proteins generated comparable in structure and function to those produced by the traditional techniques?
 
 
To find out, Drs. Tamara Otto and Douglas Cerasoli of the US Army Medical Research Institute of Chemical Defense and Dr. George Buchman of Chesapeake PERL Inc. turned to Dr. Harry Greenblatt and Prof. Joel L. Sussman of the Weizmann Institute’s Structural Biology Department (Faculty of Chemistry) to decipher the structure of the enzyme human carboxylesterase 1, produced using the new system. This enzyme, already well characterized using cell culture techniques, is expressed primarily in the liver and is thought to be responsible for the breakdown of drugs. With slight modifications to its design, it also holds promise as an antidote against insecticides and even nerve gas agents.

Using the state-of-the-art facilities at the Israel Structural Proteomics Center (ISPC) at the Weizmann Institute, of which Sussman is Director, and combining various functional analysis, crystallization and data collection methods, Greenblatt was able to crystallize the human carboxylesterase 1 enzyme isolated from the larvae and confirm that its structure – and function – was identical to previous examples of this enzyme isolated from cultured insect cells.
 
cabbage looper caterpillar
 
This proof of principle study validates the use of whole insects as a new resource for producing human proteins. “Not only are these moth larvae easy to grow and manipulate,” says Greenblatt, “they are also cheaper than cell culture techniques and even produce a larger quantity of protein.”

Sussman: “So far, we have tested only the human carboxylesterase 1 enzyme; but if this new system proves to work for other proteins as well, it will provide an invaluable tool for researchers and industry, alike.”

A page on this study can be seen in Proteopedia at: http://www.proteopedia.org/w/Journal:Acta_Cryst_F:1
 
Prof. Joel Sussman’s research is supported by Yossie and Dana Hollander, Israel, the Samuel Aba and Sisel Klurman Foundation; the Bruce H. and Rosalie N. Rosen Family Foundation; and the Nalvyco Trust. Prof. Joel Sussman is the incumbent of the Morton and Gladys Pickman Professorial Chair in Structural Biology.
 
Cabbage looper caterpillar in its native habitiat. Image: David Cappaert, Michigan State University
Chemistry
English

A Cellular Microprocessor Keeps Its Cool

English

 

Dr. Eran Hornstein
 
Microprocessors – at least in the cell – are complexes that chop active, non-protein-coding strands called microRNAs (miRNA) out of longer, inactive precursor miRNA strands. These functional miRNAs regulate protein production by inhibiting the capacity of the RNAs that do code for proteins.

Dr. Eran Hornstein, Prof. Naama Barkai and former Ph.D. students Drs. Omer Barad and Mati Mann of the Molecular Genetics Department asked how the Microprocessor complex manages to cut the right precursor miRNA strands and avoid cutting other forms of RNA that may present similar structures to those targeted by the chopping machinery. In research that appeared in Nature Structural and Molecular Biology, they used both mathematical modeling and experiments in cells to show how the Microprocessor machinery balances the interplay between efficiency and specificity in the production of miRNAs.
 
 
“On the one hand, it should not be overly specific, as this may come at the cost of also cleaving unwanted nonspecific RNA substrates. On the other hand, it should not be too ‘picky’ because of the risk that this will result in insufficient efficiency at processing genuine miRNAs,” says Hornstein.

They predicted that the balance between efficiency and specificity would be maintained via a feedback loop in which the Microprocessor detects the amount of precursor miRNA available in the cell and alters its own production accordingly. After checking in mouse and human tissue, they found that the Microprocessor is indeed attuned to levels of precursor miRNA, upping its own production if the cell is inundated with precursor miRNA, or halting production in response to a decrease in the flow of precursors.
 
Hornstein_microprocessor
 
Since small RNAs are produced synthetically as possible new therapies for a number of diseases, this research may direct efforts toward efficiently producing such therapies in the future. In addition, many other biological systems need to balance efficiency with specificity, and the team’s findings suggest that many may do so in a similar way.
 
Prof. Naama Barkai’s research is supported by the Azrieli Institute for Systems Biology, which she heads; the Helen and Martin Kimmel Award for Innovative Investigation; the Jeanne and Joseph Nissim Foundation for Life Sciences Research; Lorna Greenberg Scherzer, Canada; the Carolito Stiftung; the European Research Council; the estate of Hilda Jacoby-Schaerf; and the estate of John Hunter. Prof. Barkai is the incumbent of the Lorna Greenberg Scherzer Professorial Chair.
 
Dr. Eran Hornstein’s research is supported by Dr. Sidney Brenner and Friends; the Carolito Stiftung; the Nella and Leon Benoziyo Center for Neurological Diseases; the Y. Leon Benoziyo Institute for Molecular Medicine; the Nathan, Shirley, Philip and Charlene Vener New Scientist Fund; the estate of Fannie Sherr; the estate of Lola Asseof; Maria Halphen, France; the Julius and Ray Charlestein Foundation; the Legacy Heritage Fund; the Kekst Family Institute for Medical Genetics; the David and Fela Shapell Family Center for Genetic Disorders Research; the Helen and Martin Kimmel Institute for Stem Cell Research; the Crown Human Genome Center; the Celia Benattar Memorial Fund for Juvenile Diabetes; the Fraida Foundation; and the Wolfson Family Charitable Trust. Dr. Hornstein is the incumbent of the Helen and Milton A. Kimmelman Career Development Chair.
 
 
Hornstein_microprocessor
Life Sciences
English

Finding the Source of Cancer Recurrence

English

Prof. Ehud Shapiro, Dr. Rivka Adar, Adam Spiro and Noa Chapal-Ilani

 

 

 
 
 
 
 
 
 
 
 
 
 
 
Long after a cancer has been beaten into remission, it can return. New research led by Institute scientists recently provided strong evidence that in leukemia, at least, this is due to cancer stem cells – cells that divide slowly and are thus immune to the attacks of the chemotherapy drugs that target only the rapidly dividing cells. Nonetheless, they are capable of generating new cancer cells that divide rapidly.

In recent years, scientists have been finding signs of these cancer stem cells. Such cells are thought to hide in the body long after the chemotherapy has eradicated the main cancer growth, eventually giving rise to new cancer. But it has been unclear whether these cells really are the source of renewed cancer or whether the new growth simply comes from a small population of “ordinary” cancer cells that managed by chance to survive the treatment.

Approaching the issue with a method for reconstructing cell lineage trees that he and his group have developed over the past few years, Prof. Ehud Shapiro and his team in the Biological Chemistry and the Applied Mathematics and Computer Sciences Departments worked with scientists and doctors from Rambam Medical Center and the Technion, in Haifa. In the method, a comparison of the mutations that cells have accumulated over the course of cell division enables researchers to map out the cells' “familial” relations and determine how far back they share a common ancestor.
 
 
Leukemia cells. Image: Wikimedia Commons, NIH
 
The lineage tree was based on two sets of blood samples: The first taken from leukemia patients right after the disease was diagnosed and the second from those patients in whom the cancer had returned following chemotherapy. The lineage tree showed that, at least in some of the patients, the source of the renewed cancer was not ordinary cancer cells from the earlier bout, but rather cells that were very close to the base of the cancer lineage tree. In other words, the cancer arose from cells that divide very slowly – cancer stem cells that were immune to the attacks of the chemotherapy drugs yet were capable of recreating a population of rapidly dividing cancer cells.

Shapiro: “Our results suggest that to completely eliminate recurrent leukemia, we must look for a treatment that will not only destroy the rapidly dividing cells but also target the cancer stem cells that are resistant to conventional treatment.”

Participating in the research were Dr. Liran Shlush of the Technion Faculty of Medicine and the Rambam Healthcare Campus; Noa Chapal-Ilani and Dr. Rivka Adar of the Weizmann Institute; Prof. Karl Skorecki of the Technion; Tsila Zuckerman of the Rambam Healthcare Campus; Prof. Clara D. Bloomfield of Ohio State University; and additional scientists.
 
Prof. Ehud Shapiro's research is supported by the Paul Sparr Foundation;Miel de Botton,UK;the Carolito Stiftung; and the European Research Council. Prof. Shapiro is the incumbent of the Harry Weinrebe Professorial Chair of Computer Science and Biology.
 
 
Prof. Ehud Shapiro, Dr. Rivka Adar, Adam Spiro and Noa Chapal-Ilani
Life Sciences
English

Kill the Messenger

English
 
Prof. Rony Seger
 
What’s good news for one might spell disaster for another. In cancer for instance, when a certain cell is commanded to grow and divide without restraint, it’s a welcome message for the cell itself but a tragedy for the person who harbors this cell in his or her body. Weizmann Institute scientists have managed to decipher and block one type of molecular message that prompts unbridled cellular growth.

The molecular message first arrives at the cell’s membrane, but its ultimate destination is the cell’s nucleus, which contains the DNA. It’s a huge distance for the message to cross, equivalent to 50 kilometers for a human being. To reach the nucleus quickly, the message is relayed by a chain of chemical messengers, from one molecule to another. More than two decades ago, Prof. Rony Seger of the Weizmann Institute’s Biological Regulation Department took part in the discovery of one such chain – one that participates in the induction of numerous types of cancer; among other molecules, it includes the enzymes MEK1, MEK2, ERK1 and ERK2.

At first, Seger studied the transmission of molecular messages by these enzymes in the cell’s cytoplasm. Only four years ago did he and his team succeed in uncovering the details of the later, most crucial step: the entry of the message into the cell’s nucleus. The scientists identified a segment in the enzymes called NTS. Through the addition of phosphorus molecules, NTS undergoes a change that makes the enzymes’ entry into the nucleus possible. When the researchers created a small peptide mimicking NTS, the message was blocked and failed to reach the nucleus. As a result, the cell stopped growing: Apparently, the peptide had intercepted the “Enter the nucleus!” command. In experiments with mice, the peptide effectively blocked the development of several types of cancer, particularly melanoma: Not only did the tumors stop growing, they disappeared entirely.

Seger’s findings are currently being considered for future biotechnological applications.
 
Prof. Rony Seger's research is supported by the M.D. Moross Institute for Cancer Research; the Willner Family Center for Vascular Biology, which he heads; the Aharon Katzir-Katchalsky Center, which he heads; the Phyllis and Joseph Gurwin Fund for Scientific Advancement; and Katy and Gary Leff, Calabasas, CA. Prof. Seger is the incumbent Yale S. Lewine & Ella Miller Lewine Professorial Chair for Cancer Research.



 
 
Life Sciences
English

Two for the Price of One

English
 
 
Cover illustration: the zebrafish stress response
 
After we sense a threat, our brain center incharge of responding goes into gear, setting off a chain of biochemical reactions leading to the release of cortisol – a main stress hormone – from the adrenal glands.

Dr. Gil Levkowitz and his team in the Molecular Cell Biology Department have now revealed a new kind of ON-OFF switch in the brain for regulating the production of a main biochemical signal from the brain that stimulates cortisol release in the body. This finding, which appeared in Neuron, may be relevant to research into a number of stress-related neurological disorders.
 
This signal is corticotropin releasing hormone (CRH), which is manufactured and stored in special neurons in the hypothalamus. By the time the CRH-containing neurons have depleted their supply of the hormone, they are already receiving the directive to produce more.

The research – on zebrafish – was performed in Levkowitz’s lab and spearheaded by Dr. Liat Amir-Zilberstein together with Drs. Janna Blechman, Adriana Reuveny and Natalia Borodovsky, as well as Maayan Tahor. The team found that a protein called Otp is involved in several stages of CRH production. As well as directly activating the genes encoding CRH, it also regulates the production of two different receptors on the neurons’ surface for receiving and relaying CRH production signals – in effect, ON and OFF switches.

The researchers discovered that both receptors are encoded in a single gene. To get two receptors for the price of one, Otp regulates a gene-editing process known as alternative splicing, in which some of the elements in the sequence encoded in a gene can be “cut and pasted” to make slightly different “sentences.” In this case, it generates two variants of a receptor called PAC1: The short version produces the ON receptor; the long version, containing an extra sequence, encodes the OFF receptor. The researchers found that as the threat passed and the supply of CRH was replenished, the ratio between the two types of PAC1 receptor on the neurons’ surface gradually changed from more ON to mostly OFF.
 
Faulty switching mechanisms may play a role in a number of stress-related disorders. The action of the PAC1 receptor has recently been implicated in post-traumatic stress disorder, as well as in schizophrenia and depression. Malfunctions in alternative splicing have also been associated with epilepsy, mental retardation, bipolar disorder and autism.
 
Dr. Gil Levkowitz's research is supported by the estate of Lore Lennon; the Kirk Center for Childhood Cancer and Immunological Disorders; the Dekker Foundation; and the Irwin Green Alzheimer's Research Fund. Dr. Levkowitz is the incumbent of the Tauro Career Development Chair in Biomedical Research.


 
 
Cover illustration: the zebrafish stress response
Life Sciences
English

At the Core

English
 
ISPC illustration
"Structural Biology is a scientific area in which Israeli scientists have been leading for many years, as evidenced by the Weizmann Institute's Prof. Ada Yonath, who won a Nobel Prize in 2009 for her pioneering work on solving the structure of ribosomes," says the Institute's Prof. Joel Sussman, Director of Israel’s Instruct Core Centre.

This Centre, which is operated jointly with Tel Aviv University, is one of seven Core Centres recently founded in prestigious institutions, mainly in Europe. They are a part of Instruct (Integrated Structural Biology Infrastructure), which aims to give pan-European users access to state-of-the-art equipment, technologies and manpower in cellular structural biology. This will enable Europe to maintain a competitive edge and play a leading role in this vital research area.

Central to the decision to locate the Instruct Core Centre in Israel is the Israel Structural Proteomics Center (ISPC) established by scientists from the Weizmann Institute, with Sussman as its director, to increase the efficiency of protein structure determination.

The founding agreement, signed in February at a ceremony in Brussels, will mean that "Israeli scientists and their European counterparts will now have access to facilities they could only have dreamed of before," says the Weizmann Institute’s Prof. Gideon Schreiber, Deputy Director of Israel's Instruct Core Centre as well as of the ISPC. "We hope this core centre will stimulate new collaborative research projects between laboratories throughout Europe with the Weizmann Institute as well as with other Israeli institutions, and also attract more graduate students, postdoctoral fellows and visiting scientists from all over the world."
 
Prof. Joel Sussman's research is supported by Mr. and Mrs. Yossie Hollander, Israel; the Jean and Jula Goldwurm Memorial Foundation; the Samuel Aba and Sisel Klurman Foundation; the Bruce H. and Rosalie N. Rosen Family Foundation; Mr. and Mrs. Howard Garoon, Glencoe, IL; and the Nalvyco Trust. Prof. Joel Sussman is the incumbent of the Morton and Gladys Pickman Professorial Chair in Structural Biology.
 

 

 
 Israel Structural Proteomics Center (ISPC) illustration
Chemistry
English

New Center Looks to the Past

English

 

 Dr. Elisabetta Boaretto and Prof. Stephen Weiner

When did modern humans arrive in Europe and Asia? At what rate have cultural changes spread from one region to another throughout history? How did Neanderthal teeth and bones differ from ours? These and many other topics will be investigated at the new Max Planck – Weizmann Institute of Science Center in the Field of Integrative Archaeology and Anthropology.

The Center’s directors are Prof. Stephen Weiner of the Weizmann Institute and Prof. Jean-Jacques Hublin of the Max Planck Institute for Evolutionary Anthropology. Activities in the Center will be undertaken by two groups of scientists, in Israel and in Germany, each consisting of approximately 10 scientists and students. In addition to performing their own research, the groups will engage in collaborative activities between the Weizmann Institute and the Max Planck Institute.

Two separate tracks will focus on “The Timing of Cultural Change” and “Physical Anthropology through Bone and Tooth Structure-Function Studies,” and both will make use of scientific and technological advances developed in Weizmann Institute labs.

Among these advances is the planned installation of new accelerator mass spectrometry (AMS) equipment in the Institute’s Physics Faculty. The new radiocarbon lab, directed by Dr. Elisabetta Boaretto, is expected to have a major impact on archaeology research both locally and internationally. Because the AMS – which will be the only machine of its kind in the entire Middle East – is capable of detecting C-14 in extremely minute concentrations, it will be possible to perform the dating very fast and on minute quantities of material, such as a single lentil or grain of wheat, or a small trace of collagen in bones. This is an essential feature, because over thousands of years, organic matter on which radiocarbon dating is based tends to diminish and disappear. The new AMS lab, made possible by a gift from Dr. Naim Dangoor CBE of London, founder and head of the Exilarch's Foundation, is expected to be the first radiocarbon-dating laboratory in the world dedicated to research rather than to providing a service.
 
Prof. Stephen Weiner's research is supported by the Exilarch's Foundation; the Maurice and Vivienne Wohl Charitable Foundation; the estate of Hilda Jacoby-Schaerf; the Helen and Martin Kimmel Center for Archaeological Science, which he heads; the European Research Council; and the J&R Center for Scientific Research. Prof. Weiner is the incumbent of the Dr. Walter and Dr. Trude Borchardt Professorial Chair in Structural Biology.
 

 

 
 Dr. Elisabetta Boaretto and Prof. Stephen Weiner
Scientific Archaeology
English
Yes

Weizmann Invention: Visual Summarization

English
 
 
Prof. Michal Irani
 
Yeda Research and Development, Ltd., the commercial arm of the Weizmann Institute of Science, recently entered into a license agreement with Adobe Systems Incorporated related to a bidirectional similarity measure to summarize visual data.
 
The bidirectional similarity method developed by Prof. Michal Irani and Drs. Denis Simakov, Yaron Caspi and Eli Shechtman of the Institute’s Computer Science and Applied Mathematics Department can be used on both still images and videos. The method produces a complete and coherent visual summary – a smaller or shorter version of the original that retains the most relevant information. The bidirectionality of the method ensures that the resulting image is visually coherent: In addition to telling the same “story,” it is as visually satisfying as the original. As opposed to cropping or clipping, in which important information can be lost; or scaling down, in which resolution is lost, summarizing manages to maintain relevant information as well as resolution details, despite the decrease in size. 
 

The method is based on eliminating redundant information from the image/video. Video summarization works in a similar way, except that the program exploits redundancy in space-time. Gradual resizing and rechecking ensures that the final result is seamless and coherent.



In addition to summarizing images and videos, the method may have a number of other applications: completing missing parts in images/videos; creating montages out of separate images; photo reshuffling (in which elements in the image/video can be moved around); automatic cropping; image synthesis (in which an image can be expanded, rather than summarized); and image morphing (generating a video sequence that displays a smooth transition from one image to another, possibly unrelated, image).

Prof. Michal Irani's research is supported by the Citi Foundation.

 
 

(l-r) Before and after images showing summarization with the bidirectional similarity measure. All of the relevant visual information is preservedsummarized image

 


Original video

 


Summarized video

 

 

The "Before image" of Visual Summarization
Math & Computer Science
English

Doubly Prepared

English

 

Naama Barkai
Prof. Naama Barkai

Sugar, cholesterol, phosphates, zinc – a healthy body is amazingly good at keeping such vital nutrients at appropriate levels within its cells. From an engineering point of view, one all-purpose model of the pumps on the surface of a cell should suffice to keep these levels constant: When the concentration of a nutrient – say, sugar – drops inside the cell, the pump mechanism could simply go into higher gear until the sugar level was back to normal. Yet, strangely enough, many cells are known to use two types of pump: One is active in “good times,” when a particular nutrient is abundant in the cell’s environment; the other is a “bad-times” pump that springs into action only when the nutrient becomes scarce. Why does the cell need this dual mechanism?

A new Weizmann Institute study, reported in Science, might provide the answer. The research was conducted by Dr. Sagi Levy, Moshe Kafri and Miri Carmi in the lab of Prof. Naama Barkai of the Molecular Genetics Department.

In their new study, the scientists discovered that cells which repress their “bad-times” pumps when a nutrient is abundant were much more efficient at preparing for starvation and at recovering afterwards than the cells that had been genetically engineered to avoid this repression. Apparently, the “good-times” pumps serve as a signaling mechanism that warns the yeast cell of approaching starvation, giving the cell more time to stock up on the scarce nutrient and helping the cell to start growing faster once starvation is over.

Wild type yeast cells (l) exhibit changes in the membrane pump proteins under different nutrient conditions, while yeast engineered to avoid repressing one transporter type (r) show no change
 

Thus the dual-pump system appears to be part of a regulatory mechanism that enables the cell to deal effectively with fluctuations in nutrient supply. If these findings prove to be applicable to human cells, they could explain how our bodies maintain adequate levels of various nutrients in tissues and organs. Understanding dual-pump regulation could be crucial because mishaps in the process might contribute to various metabolic disorders.

Prof. Naama Barkai's research is supported by the Helen and Martin Kimmel Award for Innovative Investigation; the Jeanne and Joseph Nissim Foundation for Life Sciences Research; the Carolito Stiftung; Lorna Greenberg Scherzer, Canada; the estate of John Hunter; the Minna James Heineman Stiftung; the European Research Council; and the estate of Hilda Jacoby-Schaerf. Prof. Barkai is the incumbent of the Lorna Greenberg Scherzer Professorial Chair.

 

 
Wild type yeast cells (l) exhibit changes in the membrane pump proteins under different nutrient conditions, while yeast engineered to avoid repressing one transporter type (r) show no change
Life Sciences
English

Hidden Passage

English
Electron microscope image of an effector cell inserting several appendages through endothelial cell membranes
 
The white blood cells that fight disease and help the body heal are directed to sites of infection or injury by “exit signs” – chemical signals that tell them where to pass through the blood vessel walls and into the underlying tissue. Such signs consist of migration-promoting molecules called chemokines, which the cells lining the blood vessels display on their outer surfaces like flashing lights.
 
In previous research, Prof. Ronen Alon and his team in the Immunology Department had shown that white blood cells crawl on dozens of tiny legs along the endothelial cells on the inner surface of blood vessels, feeling their way to the chemokines. But in new research, which appeared in Nature Immunology, Alon, together with Drs. Ziv Shulman and Shmuel Cohen, found that sometimes those chemokines are stashed away in tiny containers – vesicles – just inside the inflamed endothelial cells.
 
 
In this case, only certain immune cells, called effector cells, are able to find the chemokines and thus exit the blood vessels. Effector cells are “educated”: They learn to identify particular pathogens in the lymph nodes before returning to the bloodstream to seek them out. Alon and his team observed that as effector cells sought out hidden chemokines near inflammation sites, they paused in the joins where several endothelial cells meet and extended their legs right through the endothelial cell membranes. Once they obtained the right chemokine directives, the effector cells were quickly ushered out through the blood vessel walls toward their final destination.
 
 

Effector cells, tagged green, seem to fade as they detect chemokines and move inward, past the surface of the blood vessel endothelium

 

 

 

Effector cells in an experimental control move on endothelium that does not produce internal chemokines

 

Prof. Ronen Alon
 
The researchers think that this game of “hide and seek” both preserves the chemokine signal and acts as a “selector” that permits only “trained” effector cells to exit the bloodstream. Alon: “We think that tumors near blood vessels might exploit these traffic rules by putting the endothelial cells in a quiescent state or making the endothelium produce the ‘wrong’ chemokines. Immune cells capable of destroying these tumors would then be unable to reach the tumor site, whereas those that aid in cancer growth will easily pass through to them.”
 
Prof. Ronen Alon’s research is supported by the Helen and Martin Kimmel Institute for Stem Cell Research; and the Kirk Center for Childhood Cancer and Immunological Disorders. Prof. Alon is the incumbent of the Linda Jacobs Professorial Chair in Immune and Stem Cell Research.
 
Electron microscope image of an effector cell inserting several appendages through endothelial cell membranes
Life Sciences
English

Pages